L'Oncodaily Session during London Cancer Week 2026
Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit
FASCO 2027: Recognizing Dedication to Oncology
Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission
Top Gastroesophageal Cancer Updates From ESMO 2026
Arun Azad: New TALAPRO-2 Data Highlight the Prognostic Value of ctDNA and CTCs in Prostate Cancer
Jeff Dunn on Cancer Equity: The Powerful Message Behind “Poverty Is a Carcinogen”
A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer
